ER-KANG(300267)2024-10-10 13:56Financial Performance - In the first half of 2024, the company's traditional Chinese medicine products achieved revenue of 4006.49 million yuan, a year-on-year increase of 389.56% [2] - In the first half of 2024, the company's excipients achieved revenue of 47805.62 million yuan, accounting for 76.94% of total revenue [4] - In the first half of 2024, the company's modified starch and starch capsule series products achieved revenue of 2974.14 million yuan, a year-on-year increase of 112.97% [4] R&D and Innovation - In the first half of 2024, the company's R&D investment was 2119.59 million yuan [2] - In the first half of 2024, the company obtained 12 patents, including 1 invention patent and 11 utility model patents [3] - The company is actively exploring the use of AI technology to advance the research and development of excipients, RDC drugs, and biosynthetic drugs [3][4] Strategic Projects and Partnerships - The company's wholly-owned subsidiary, Erkang Mining, has completed the construction of the first beneficiation plant in Nigeria and is accelerating equipment debugging [4][5][6] - The company is in discussions with AI technology companies and nuclear drug R&D and production companies to leverage its resource advantages [3][4] Market and Policy Response - The company is closely monitoring industry policies and trends, and will adjust its business and management strategies accordingly to mitigate risks [3] - The company is actively developing and maintaining multiple market channels, exploring new internet-based promotion and operation models [2] Future Plans and Outlook - The company plans to further optimize products and services, stabilize existing markets, and expand into new markets [4] - The company is considering the use of AI technology to drive long-term and sustainable development [3] - The company is accelerating the debugging of equipment at its beneficiation plant in Nigeria, aiming to start production as soon as possible [4][5][6]